MARKET

SBPH

SBPH

Spring Bk Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.460
-0.030
-2.01%
Closed 16:28 08/12 EDT
OPEN
1.500
PREV CLOSE
1.490
HIGH
1.530
LOW
1.420
VOLUME
122.55K
TURNOVER
--
52 WEEK HIGH
4.800
52 WEEK LOW
0.8000
MARKET CAP
25.18M
P/E (TTM)
-0.8886
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SBPH stock price target is 1.750 with a high estimate of 2.000 and a low estimate of 1.500.

EPS

SBPH News

More
Spring Bank Q2 EPS $(0.38) Down From $(0.28) YoY
Spring Bank (NASDAQ:SBPH) reported quarterly losses of $(0.38) per share. This is a 35.71 percent decrease over losses of $(0.28) per share from the same period last year.
Benzinga · 2d ago
SPRING BANK PARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Spring Bank Pharmaceuticals, Inc. - SBPH
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Spring Bank Pharmaceuticals, Inc. (NasdaqGS: SBPH) ("the Company") with F-star Therapeutics, Limited in
PR Newswire · 6d ago
SPRING BANK PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger
WILMINGTON, Del., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Spring Bank Pharmaceuticals, Inc. (“Spring Bank”) (NASDAQ GS: SBPH) regarding possible breaches of fiduciary duties and other violations of law relate
GlobeNewswire · 08/04 13:42
SPRING BANK ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SBPH and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) breached their fiduciary duties or violated the federal securitie
Business Wire · 08/03 19:33
Spring Bank Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Spring Bank Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm
Halper Sadeh LLP, a global investor rights law firm, is investigating whether Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection
PR Newswire · 08/01 14:05
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Spring Bank Pharmaceuticals, Inc.
Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the proposed merger of the company with F-star Therapeutics, Limited. Spring Bank Pharmaceuticals sto
Business Wire · 07/31 17:35
TAOP, KODK among premarket losers
Seeking Alpha · 07/31 12:16
Spring Bank Pharma to merge with F-Star Therapeutics in all-stock deal
Seeking Alpha · 07/30 15:37

Industry

Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
+1.79%

Hot Stocks

Symbol
Price
%Change

About SBPH

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.
More

Webull offers kinds of Spring Bank Pharmaceuticals Inc stock information, including NASDAQ:SBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SBPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SBPH stock methods without spending real money on the virtual paper trading platform.